Allergic conjunctivitis therapy widens past topical antihistamines
Topical multi-action options, novel mechanism programs, and emerging biologic-pathway therapy are reshaping allergic conjunctivitis management.
Allergic conjunctivitis has been a topical antihistamine and mast cell stabiliser category for years. Multi-action topical agents (combining antihistamine plus mast cell stabiliser plus other mechanisms) are now standard, novel mechanism programs (TRPM8, others) are in late-stage trials, and biologic-pathway therapy (dupilumab off-label use in vernal and atopic keratoconjunctivitis, follow-on programs) is reshaping severe disease management. The cross-condition atopic-cluster integration (covered in earlier rounds) supports biologic use in severe ocular allergy.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.